Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Current Molecular Imaging Positron Emitting Radiotracers in Oncology Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with non-invasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18F-fluorodeoxyglucose (18F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/current-molecular-imaging-positron-emitting-radiotracers-in-oncology-F0wpXEq0ox

References (170)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Orthopedics; Oncology; Nuclear Medicine
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-011-0075-y
pmid
24899972
Publisher site
See Article on Publisher Site

Abstract

Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with non-invasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18F-fluorodeoxyglucose (18F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors.

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Feb 1, 2011

There are no references for this article.